APR 17, 2019 5:23 PM PDT

Using Engineered Bacteria to Rapidly Evaluate Therapeutics

WRITTEN BY: Carmen Leitch

Scientists are using genetic tools to engineer bacteria in many ways. These new microbes are able to mimic or sense disease states, so that researchers can use them to study illness, like infectious pathogens or cancer. These genetic techniques that program bacterial cell behavior can also be used to create circuits that not only act as sensors but are also responders, for example, creating therapeutic molecules in certain situations. These engineered microbes can also be used to test treatments or act as delivery systems, like a kind of living medicine. 

Now, scientists from Columbia Engineering report a method for using programmed bacteria as a kind of miniaturized tissue that can model tumors. The technique, called "bacteria spheroids co-culture," or BSCC, has been reported in the Proceedings of the National Academy of Sciences (PNAS); it is a high-speed method for rapidly evaluating therapeutics.

The image shows engineered bacteria (green) in tumor spheroids cultured in a multi-well plate. / Credit: Tetsuhiro Harimoto/Columbia Engineering

"We're very excited at how efficient BSCC is and think it will really accelerate engineered bacterial therapy for clinical use," said the research leader Tal Danino, an assistant professor of biomedical engineering. "By combining automation and robotics technology, BSCC can test a large library of therapies to discover effective treatments. And because BSCC is so broadly applicable, we can modify the system to test human samples as well as other diseases. For example, it will help us personalize medical treatments by creating a patient's cancer in a dish, and rapidly identify the best therapy for the specific individual."

The microenvironment of a tumor impairs the local immune response, and bacteria that would be killed if it was elsewhere in the body is able to grow in the tumor. The researchers used that knowledge; they used an antimicrobial agent, an antibiotic called gentamicin, and cultured bacteria in spheroids, mimicking tumors in the body. With the BSCC technique, they were able to quickly assess many different programmed anticancer bacterial therapies like genetic circuits or engineered microbes.

Bacteria colonize multicellular spheroids in vitro where they are screened for growth, circuit dynamics, and therapeutic efficacy and then are validated in mouse tumor models. / Credit: Tetsuhiro Harimoto/Columbia Engineering

"We used 3D multicellular spheroids because they recapitulate conditions found in the human body, such as oxygen and nutrient gradients; these can't be made in a traditional 2D monolayer cell culture," said the lead author of the report Tetsuhiro Harimoto, a graduate candidate working in Danino's lab. "In addition, the 3D spheroid provides bacteria with enough space to live in its core, in much the same way that bacteria colonize tumors in the body, also something we can't do in the 2D monolayer culture. Plus, it's simple to make large numbers of 3D spheroids and adapt them for high-throughput screening."

The team was able to use BSCC as a high-throughput way to characterize batches of programmed bacteria and identify those that show the most promise. They found a novel bacterial toxin called theta toxin, which has significant impacts on colon cancer when combined with a delivery circuit that uses attenuated Salmonella Typhimurium. Anticancer therapeutic efficacy was also improved by some bacterial therapeutics they tested.

The scientists are hopeful that this work will have additional applications. They would like to use BSCC for microbial therapeutics that apply to other diseases, like infectious illnesses and gastrointestinal disorders. 

Sources: AAAS/Eurekalert! via Columbia University School of Engineering and Applied Science, PNAS

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
OCT 21, 2020
Microbiology
The First Treatment for Ebola is Approved by FDA
OCT 21, 2020
The First Treatment for Ebola is Approved by FDA
Ebola virus can pass from animals to humans, and between people. Rarely, it causes outbreaks but when it does, they can ...
NOV 16, 2020
Cell & Molecular Biology
How Gut Microbes Deactivate a Common Diabetes Drug
NOV 16, 2020
How Gut Microbes Deactivate a Common Diabetes Drug
Metformin is a frequently prescribed type 2 diabetes treatment but its effects can vary significantly. In some patients ...
NOV 28, 2020
Microbiology
Potential Treatment ID'ed for Emerging Viral Disease
NOV 28, 2020
Potential Treatment ID'ed for Emerging Viral Disease
A mosquito-borne virus called VEEV has been emerging in South America. It causes symptoms that make it difficult to dist ...
NOV 30, 2020
Microbiology
Common Antibiotic Could be Effective Zika Treatment
NOV 30, 2020
Common Antibiotic Could be Effective Zika Treatment
Zika virus cause a devastating epidemic in 2015, and led to the birth of hundreds of children that had congenital brain ...
JAN 06, 2021
Immunology
Probiotic Boosters Are Lifesavers for Preterm Babies
JAN 06, 2021
Probiotic Boosters Are Lifesavers for Preterm Babies
When administered shortly after birth, a recent study has found that the supplementation combo of probiotics and prebiot ...
JAN 24, 2021
Microbiology
Cholesterol Enables SARS-CoV-2 to Invade & Create 'Mega-Cells'
JAN 24, 2021
Cholesterol Enables SARS-CoV-2 to Invade & Create 'Mega-Cells'
To cause the COVID-19 illness, the SARS-CoV-2 virus first has to get into cells. To do so, it uses something called a sp ...
Loading Comments...